Prostate Cancer clinical trials
Showing 201–250 of 735 active trials. Describe your situation to see which ones you may be eligible for.
- Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
- MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
- Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
- First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
- Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
- Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
- Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
- TERPS Trial for de Novo Oligometastic Prostate Cancer
- Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
- Castrate Resistant Prostate Cancer Enhertu Therapy
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
- Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
- Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors
- Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer
- Preop Laxatives in Robotic Urologic Surgery
- PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
- Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
- Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
- Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
- Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
- Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
- Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
- HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- A Study of Changes to Prostate Procedures
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.